In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
HIGHLIGHTS
EVENTS
Leading medical-scientific event on Hemophilia held in Trieste, Italy
Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight
read moreEVENTS
Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy
A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN
read morePLASMA & BIOTHERAPIES
First patient enrolled and treated in Kedrion’s CARES10 clinical study
Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients
read more-
EVENTS - 06-06-2013
Haemopilia, Kedrion supports the workshop on the efficiency of the blood system
read more -
CORPORATE - 31-05-2013
Grifols transfers to Kedrion the management of the plasma fractionation plant of Melville (USA), owned by Kedrion
read more
Pages
For more information please contact: pressoffice@kedrion.com
Where 